OBJECTIVES: Current treatments for chronic hepatitis C (CHC) are frequently associated with complex regimens and serious adverse events. Little is known about the impact of these treatment attributes on health state utilities. The purpose of this study was to estimate the utility or disutility (i.e., utility decrease) associated with treatment administration and adverse events of CHC treatments. METHODS: Health states were drafted based on literature review and expert clinician interviews.  General population participants in the UK (London, Edinburgh) valued the health states in time trade-off (TTO) interviews with both 10-year and 1-year time horizons.  The 14 health states described hepatitis C with variations in treatment attributes: number of tablets per day, weekly injection, fatty food requirement, and six adverse events. RESULTS: A total of 182 participants completed interviews (50% female; mean age = 39.3y).  In treatment regimens without injections, greater numbers of tablets were associated with slightly lower utility (1 tablet = 0.80; 2 tablets = 0.80; 3 tablets = 0.80; 7 tablets = 0.79).  Utilities for health states describing regimens with oral and injectable medication were 0.77 (7 tablets), 0.75 (12 tablets), and 0.71 (18 tablets).  Addition of a weekly injection to a 7-tablet regimen had a disutility of -0.02.  The requirement to take tablets with fatty food had a disutility of -0.04.  Adverse events were associated with substantial disutilities: mild anemia, -0.12; severe anemia, -0.32; flu-like symptoms, -0.21; mild rash, -0.13; severe rash, -0.48; depression, -0.47.  These utilities are from the 10-year TTO; one-year scores were very similar. CONCLUSIONS: Adverse events and greater treatment regimen complexity were associated with utility reductions, suggesting a perceived decrease in quality of life beyond the impact of hepatitis C itself.  The resulting utilities may be used in models estimating and comparing the value of treatments for hepatitis C.